GYREGYRE THERAPEUTICS, INC.同业对比
GYRE THERAPEUTICS, INC. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GYRE本股 | $747M#9 | — | 6.9x#13 | 6.4x#6 | 10.2%#7 | -44.8%#14 | 9.9%#4 | 9.2%#5 | 12.0%#4 | 3#3 | -9.4%#11 | 6.0%#1 |
| ARDX | $837M#2 | — | 5.6x#11 | 2.1x#2 | 22.1%#5 | -59.0%#15 | -10.1%#5 | -41.6%#11 | -52.3%#7 | — | -47.7%#14 | — |
| OLMA | $838M#1 | — | 1.9x#2 | — | — | -25.5%#11 | — | -37.7%#9 | — | — | 21.4%#9 | — |
| RIGL | $834M#4 | 2.6x#1 | 2.0x#3 | 2.8x#4 | 64.1%#3 | 1999.1%#2 | 42.6%#1 | 86.3%#1 | 30.6%#3 | — | 27.5%#8 | — |
| CYRX | $835M#3 | — | 1.7x#1 | 4.7x#5 | 12.4%#6 | 168.2%#4 | -20.9%#6 | 16.0%#4 | -16.5%#5 | 4#1 | — | — |
| GERN | $826M#5 | — | 3.8x#8 | 3483.5x#10 | -60.2%#10 | 52.2%#5 | -28938.8%#10 | -38.2%#10 | -24.8%#6 | — | 2.4%#10 | — |
| CLYM | $820M#6 | — | 3.4x#7 | — | — | 19.0%#7 | — | -25.0%#7 | — | — | 608.7%#1 | — |
| DSGN | $794M#7 | — | 3.9x#9 | — | — | -40.7%#13 | — | -34.6%#8 | — | — | — | — |
| ACRS | $773M#8 | — | 6.2x#12 | 98.7x#9 | -58.2%#9 | 50.8%#6 | -975.9%#9 | -52.1%#13 | -65.8%#8 | 3#3 | 186.1%#4 | — |
| COLL | $725M#10 | 17.5x#4 | 2.3x#4 | 0.9x#1 | 23.6%#4 | -8.7%#9 | 23.0%#3 | 20.2%#3 | 62.0%#1 | 4#1 | -37.5%#13 | — |
| NVCT | $711M#11 | — | 78.2x#15 | — | — | -39.2%#12 | — | -291.1%#14 | — | — | 251.8%#2 | — |
| MNPR | $699M#12 | — | 5.3x#10 | — | — | 12.0%#8 | — | -10.5%#6 | — | — | 83.0%#6 | — |
| ZVRA | $695M#13 | 12.6x#3 | 3.2x#6 | 6.5x#7 | 350.9%#1 | 178.9%#3 | -59.1%#7 | 38.2%#2 | — | — | 61.3%#7 | — |
| IRWD | $691M#14 | 5.3x#2 | — | 2.3x#3 | -15.7%#8 | 2629.5%#1 | 33.3%#2 | — | 42.6%#2 | — | 222.8%#3 | — |
| NGNE | $689M#15 | — | 3.2x#5 | — | -100.0%#11 | -20.2%#10 | — | -41.6%#12 | — | — | 98.0%#5 | — |
| VSTM | $657M#16 | — | 13.1x#14 | 21.2x#8 | 209.1%#2 | -60.3%#16 | -550.3%#8 | -419.1%#15 | — | — | -20.5%#12 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-16。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议